• Shufeng Xingbi Therapy in Allergic Rhinitis Rats

  2026-10-03

  A 2025 bioRxiv preprint examined how Shufeng Xingbi Therapy affects allergic rhinitis in rats through behavioral, nasal-tissue, immune, and gut-microbiota endpoints. The reported improvements are consistent with coordinated changes in allergic inflammation and intestinal metabolites, but the preprint design does not establish clinical efficacy or prove a causal microbiota mechanism.

• DNase I (RNase-free) for Reliable Assays

  2026-10-02

  Learn how DNase I (RNase-free), SKU K1088, can reduce DNA-related confounding in RNA extraction, RT-PCR, and in vitro transcription workflows supporting cell viability, proliferation, and cytotoxicity studies. This scenario-based guide connects enzyme mechanism, protocol controls, transcript-quality interpretation, and practical supplier selection.

• ML133 HCl: An Assay-First Guide to Kir2.1

  2026-10-01

  ML133 HCl is a selective potassium channel inhibitor for dissecting Kir2.1-dependent potassium ion transport. This assay-first guide connects its pH-sensitive pharmacology with pulmonary artery smooth muscle cell proliferation research, experimental controls, and the mechanistic findings of a peer-reviewed pulmonary hypertension study.

• METTL14–DHRS4-AS1 Axis in Ulcerative Colitis

  2026-10-01

  This study identifies METTL14-dependent m6A regulation of the lncRNA DHRS4-AS1 as a protective mechanism in ulcerative colitis. Its cell and mouse experiments connect METTL14 to the DHRS4-AS1/miR-206/A3AR axis, NF-κB activation, apoptosis, and inflammatory tissue injury, offering a mechanistic framework for studying RNA methylation in intestinal inflammation.

• Cyclic di-GMP: From Biofilms to STING

  2026-09-30

  Cyclic di-GMP is an intracellular second messenger linking bacterial persistence biology with STING-focused immune modulation research. This article translates the latest antitoxin findings into practical assay decisions while defining its responsible use in cancer immunotherapy studies.

• Fenofibrate, PPARα–YAP Signaling, and Liver Aging

  2026-09-30

  The reference study shows that fenofibrate-induced liver enlargement and activation of the PPARα–YAP axis are preserved across several aging mouse models. Its findings clarify how aging influences hepatic hypertrophy, proliferation, and signaling responses while providing a framework for interpreting liver growth in lipid metabolism research.

• Imatinib Hydrochloride: Assay Design Beyond IC50

  2026-09-29

  Imatinib hydrochloride is a benchmark multi-target kinase inhibitor, but its value in cancer research extends beyond a single IC50 measurement. This guide connects Abl, c-Kit, and PDGFR assay design with new conformational insights into kinase dephosphorylation and offers a practical workflow for interpreting biochemical and cellular data.

• Tomivosertib Suppresses Ectopic Activity in Human DRG

  2026-09-29

  The reference study tested MNK inhibition directly in cultured human dorsal root ganglion neurons obtained from patients with radiculopathy. Tomivosertib rapidly and reversibly reduced spontaneous activity, altered action-potential and afterhyperpolarization properties, and suppressed eIF4E Ser209 phosphorylation, providing human cellular evidence for MNK signaling as a potential neuropathic-pain target.

• DPP9–KEAP1 Coupling Links Proteostasis to Redox Control

  2026-09-28

  This study identifies KEAP1 as an endogenous binding partner that stabilizes an inactive conformation of DPP9, revealing a previously unrecognized route for regulating DPP9-dependent inflammasome control. It also shows reciprocal inhibition: altered DPP9 suppresses KEAP1-mediated NRF2 degradation, connecting protease conformation, redox sensing, and antioxidant signaling.

• Tivozanib (AV-951): Reliable Cell Assay Design

  2026-09-28

  A practical, scenario-based guide to interpreting viability and cytotoxicity results with Tivozanib (AV-951), including assay design, compound handling, and data interpretation. It explains what the product information supports for SKU A2251—and what researchers should verify in their own cell models.

• Pitavastatin (NK-104): In Vitro Assay Guide

  2026-09-27

  Pitavastatin (NK-104, SKU B1124) provides a defined HMG-CoA reductase inhibitor for investigating cholesterol synthesis in cell-based assays, with a dossier-reported HepG2 reference value to help plan a pilot. Use it in controlled laboratory workflows; the available product information does not establish a specific paper-matched protocol, animal regimen, or clinical application.

• Bcl-2 Inhibition Alters Redox and Mitochondrial State

  2026-09-26

  In SW48 colon cancer cells, ABT-263 changed optical redox and mitochondrial measurements after 24 hours without a corresponding change in viability, showing that these metabolic readouts can shift independently of cell survival. The study pairs label-free autofluorescence imaging with mitochondrial and cell-state measurements, offering a useful framework for interpreting drug-response signals without treating an optical redox change as direct evidence of cell death.

• ABT-263 (Navitoclax) in Apoptosis Research

  2026-09-25

  Use ABT-263 (Navitoclax) to test whether Bcl-2-family survival signaling shapes apoptosis in cancer models, including primary ALL workflows. Pair it with cell-cycle-aware measurements to distinguish BCL-2-family dependence from the phase-specific death pathways reported after vincristine exposure.

• Lyso-Tracker Red for Live-Cell Lysosome Imaging

  2026-09-25

  Lyso-Tracker Red is a red fluorescent probe for lysosome labeling in live cells, with reported excitation and emission maxima of 577 nm and 590 nm. Lyso-Tracker Red DND-99 is a related search term, but researchers should verify the catalog identity and formulation before treating names as interchangeable.

• hiPSC Intestinal Organoids for Pharmacokinetic Studies

  2026-09-24

  Saito and colleagues report a direct 3D cluster-culture approach for generating expandable, cryopreservable intestinal organoids from human induced pluripotent stem cells. When converted to monolayers, the organoids produce intestinal epithelial cells with CYP-metabolizing and transporter activities, offering a human-relevant platform for evaluating drug disposition.

8137 records 1/543 page Next 12345 下5页 Last page